Nanobiotix S.A. filings document foreign private issuer reporting for a late-stage clinical biotechnology company developing nanoparticle-based therapeutic platforms. Recent Form 6-K reports furnish press-release exhibits covering JNJ-1900 (NBTXR3) clinical and regulatory disclosures, Nanoprimer preclinical data, operating and financial updates, and responses to corporate-status speculation.
The filing record also documents capital-structure and governance information, including share capital, theoretical and exercisable voting rights reported under French market rules, material agreements tied to development and commercialization collaborations, and foreign private issuer status on Form 20-F for its Euronext Paris and Nasdaq-listed securities.
Nanobiotix S.A. reports that the FDA has accepted a protocol amendment for the pivotal NANORAY-312 global Phase 3 study in head and neck cancer, sponsored by Johnson & Johnson. The amendment removes the planned interim analysis and changes the final analysis to be based on fewer events and to occur earlier than originally designed. Nanobiotix believes this could accelerate and broaden the global registration path for its radiotherapy-activated nanoparticle candidate JNJ-1900 (NBTXR3), potentially allowing earlier revenue generation from its licensing deal. The company notes it is eligible for hundreds of millions in aggregate milestone payments over the next few years, contingent on development and regulatory achievements in head and neck and lung cancer programs.
Nanobiotix S.A. reported new preclinical results from its Nanoprimer platform combined with lipid nanoparticle-delivered recombinant DNA (LNP-DNA) immunotherapy in a mouse model. Pre-treatment with Nanoprimer before intravenous LNP-DNA reduced liver uptake and toxicity, increased circulating LNP-DNA, and lessened cGAS-STING pathway inflammation.
The findings, presented at the 2026 American Association for Cancer Research meeting, suggest Nanoprimer may help advanced LNP systems designed for extrahepatic delivery achieve better systemic bioavailability and tolerability. The company is advancing Nanoprimer through external collaborations and an internal pipeline as a companion platform for complex therapeutics.
Nanobiotix S.A. reports its share capital and voting rights as of March 31, 2026. The company had 48,517,630 shares outstanding, corresponding to 50,165,132 theoretical voting rights and 50,143,014 exercisable voting rights. These figures are provided under French market transparency rules.
Nanobiotix S.A. reported full-year 2025 revenue and other income of €32.6 million, driven mainly by an amendment to its global licensing agreement for JNJ-1900 (NBTXR3) with Janssen and related product sales and services. Research and development expenses fell 43% to €23.1 million, reflecting the removal of most funding obligations for the NANORAY-312 study and lower development costs. Selling, general and administrative expenses were stable at €20.4 million. Net loss narrowed to €24.0 million, or €0.50 per share, compared with a net loss of €68.1 million, or €1.44 per share, in 2024.
The company closed a non-dilutive royalty financing agreement with HealthCare Royalty for up to $71 million, receiving $50 million in December 2025, and ended 2025 with €52.8 million in cash and cash equivalents. Based on its current plan and assuming receipt of the remaining $21 million from HealthCare Royalty, Nanobiotix expects this cash to fund operations into early 2028. Operationally, development of JNJ-1900 (NBTXR3) advanced across multiple tumor types, and the Curadigm Nanoprimer platform saw new patents, data, and CMC activities supporting both internal and external programs.
Nanobiotix S.A., a French oncology company listed on Euronext Paris and via ADSs on Nasdaq, files its Form 20-F for the year ended December 31, 2025. The company develops physics-based nanotechnology cancer treatments, led by JNJ-1900 (NBTXR3), now globally licensed to Janssen and in a Phase III trial called NANORAY-312.
Nanobiotix highlights extensive risk factors, including heavy reliance on Janssen for development and commercialization, complex manufacturing and technology transfer, clinical and regulatory uncertainty, and dependence on third-party CROs, CMOs and raw-material suppliers. As of December 31, 2025, it reports accumulated losses of €400.8 million, a 2025 net loss of €24.0 million and cash and cash equivalents of €52.8 million, meaning further funding will be needed. Ordinary shares outstanding were 48,410,068 as of December 31, 2025.
Nanobiotix S.A. furnished a press release highlighting first data from the Johnson & Johnson–sponsored randomized Phase 2 CONVERGE study of JNJ-1900 (NBTXR3) in stage 3 inoperable non-small cell lung cancer. Investigators reported an acceptable safety profile with no serious treatment-emergent adverse events and no impact on patients’ ability to continue planned therapy.
Among 7 patients evaluated after concurrent chemoradiotherapy and before anti-PD-L1 treatment, initial efficacy signals were encouraging, with an objective response rate of 71.4% and disease control rate of 100%, compared with an estimated 45–50% response benchmark. JNJ-1900 (NBTXR3) is a one-time intratumoral hafnium oxide nanoparticle radioenhancer activated by radiotherapy and is being developed across multiple solid tumors, including a global Phase 3 head and neck cancer trial and a global co-development agreement with Janssen.
Nanobiotix S.A. filed a report stating it will release its fourth quarter and full year 2025 financial and operational update on March 31, 2026, after the close of the U.S. market. The company will then host a conference call and webcast on April 1, 2026, at 8:00 a.m. EDT / 2:00 p.m. CEST, where senior management will review results and discuss recent business activities before taking questions. Connection details and a replay will be available in the investors section of the company’s website.
Nanobiotix S.A. filed a Form 6-K to share a press release responding to media speculation about a potential public take-over of the company. Nanobiotix states that, to the best of its knowledge, there is no intention by any party to acquire control of the company and that no process or assessment toward such a transaction is underway.
The company also notes that it has identified factual inaccuracies in the media report, which it says are not consistent with its most recent public disclosures. Beyond this clarification, the filing mainly reiterates Nanobiotix’s profile as a late-stage clinical biotechnology company developing nanotechnology-based therapies for cancer and other serious diseases.
Nanobiotix S.A. filed an update on its share capital and voting rights. As of February 28, 2026, the company had 48,494,528 shares outstanding, with 50,197,214 total theoretical voting rights and 50,175,096 exercisable voting rights, reflecting French regulatory disclosure requirements for threshold calculations.
Nanobiotix S.A. filed a Form 6-K to share a press release announcing its participation in several investor conferences in March. Company management, including CEO Laurent Levy and CFO & Business Officer Bart van Rhijn, will speak at healthcare and biotech events hosted by TD Cowen, UBS, Jefferies, and Leerink in Boston and Miami Beach. These appearances are intended to present the company’s late-stage nanotechnology-based oncology pipeline and broader platform to the investment community and other stakeholders.